Neuropsychiatric symptoms and striatal monoamine availability in early Parkinson’s disease without dementia

Yoon Sang Oh; Jean Hee Kim; Sang Won Yoo; Eo Jin Hwang; Chul Hyoung Lyoo; Kwang Soo Lee; Joong Seok Kim

doi:10.1007/s10072-020-04859-8

Neuropsychiatric symptoms and striatal monoamine availability in early Parkinson’s disease without dementia

Yoon Sang Oh, Jean Hee Kim, Sang Won Yoo, Eo Jin Hwang, Chul Hyoung Lyoo, Kwang Soo Lee, Joong Seok Kim

Department of Neurology

Research output: Contribution to journal › Article › peer-review

6 Citations (Scopus)

Abstract

Background and objective: Neuropsychiatric symptoms are relatively common in Parkinson’s disease (PD). Many studies have revealed that striatal monoamine availability is associated with specific neuropsychiatric symptoms. This study was aimed to investigate the association between comprehensive neuropsychiatric symptoms and striatal monoamine availability in patients with early PD without dementia. Methods: A total of 156 newly diagnosed patients with PD without dementia were included. All patients’ mental and behavioral problems were assessed with the 12-item Neuropsychiatric Inventory (NPI). They underwent positron emission tomography (PET) with ¹⁸F-N-(3-fluoropropyl)-2beta-carbon ethoxy-3beta-(4-iodophenyl) nortropane and brain magnetic resonance imaging (MRI). Patients were divided into no neuropsychiatric symptoms and neuropsychiatric symptoms groups according to total NPI score. After normalizing the PET images to spatially normalized MRI, regional standardized uptake value ratios (SUVRs) with a volume of interest template were analyzed for the two groups. Results: Ninety-eight patients had more than one neuropsychiatric symptom. The SUVR of the thalamus in neuropsychiatric symptoms group was significantly lower than the SUVR in no neuropsychiatric symptoms group independent of age, sex, disease duration, or severity of motor symptoms. Conclusion: Patients with early PD who have neuropsychiatric symptoms had a lower monoamine availability in the thalamus than those with no neuropsychiatric symptoms. This finding suggests that decreased monoamine transporter availability in the thalamus may be an imaging biomarker of neuropsychiatric symptoms in patients with PD.

Original language	English
Pages (from-to)	711-718
Number of pages	8
Journal	Neurological Sciences
Volume	42
Issue number	2
DOIs	https://doi.org/10.1007/s10072-020-04859-8
Publication status	Published - 2021 Feb

Bibliographical note

Funding Information:
This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT (NRF-2017R1D1A1B06028086 and NRF-2019R1G1A1099554), and by the financial support of the Catholic Medical Center Research Foundation made in the program year of 2019. The funder had no role in study design, data collection and analysis, the decision to publish or manuscript preparation.

Publisher Copyright:
© 2020, Fondazione Società Italiana di Neurologia.

All Science Journal Classification (ASJC) codes

Dermatology
Clinical Neurology
Psychiatry and Mental health

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s10072-020-04859-8

Cite this

@article{be1ecf8521eb4249a7d2da2a568ce8f5,

title = "Neuropsychiatric symptoms and striatal monoamine availability in early Parkinson{\textquoteright}s disease without dementia",

abstract = "Background and objective: Neuropsychiatric symptoms are relatively common in Parkinson{\textquoteright}s disease (PD). Many studies have revealed that striatal monoamine availability is associated with specific neuropsychiatric symptoms. This study was aimed to investigate the association between comprehensive neuropsychiatric symptoms and striatal monoamine availability in patients with early PD without dementia. Methods: A total of 156 newly diagnosed patients with PD without dementia were included. All patients{\textquoteright} mental and behavioral problems were assessed with the 12-item Neuropsychiatric Inventory (NPI). They underwent positron emission tomography (PET) with 18F-N-(3-fluoropropyl)-2beta-carbon ethoxy-3beta-(4-iodophenyl) nortropane and brain magnetic resonance imaging (MRI). Patients were divided into no neuropsychiatric symptoms and neuropsychiatric symptoms groups according to total NPI score. After normalizing the PET images to spatially normalized MRI, regional standardized uptake value ratios (SUVRs) with a volume of interest template were analyzed for the two groups. Results: Ninety-eight patients had more than one neuropsychiatric symptom. The SUVR of the thalamus in neuropsychiatric symptoms group was significantly lower than the SUVR in no neuropsychiatric symptoms group independent of age, sex, disease duration, or severity of motor symptoms. Conclusion: Patients with early PD who have neuropsychiatric symptoms had a lower monoamine availability in the thalamus than those with no neuropsychiatric symptoms. This finding suggests that decreased monoamine transporter availability in the thalamus may be an imaging biomarker of neuropsychiatric symptoms in patients with PD.",

author = "Oh, {Yoon Sang} and Kim, {Jean Hee} and Yoo, {Sang Won} and Hwang, {Eo Jin} and Lyoo, {Chul Hyoung} and Lee, {Kwang Soo} and Kim, {Joong Seok}",

note = "Funding Information: This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT (NRF-2017R1D1A1B06028086 and NRF-2019R1G1A1099554), and by the financial support of the Catholic Medical Center Research Foundation made in the program year of 2019. The funder had no role in study design, data collection and analysis, the decision to publish or manuscript preparation. Publisher Copyright: {\textcopyright} 2020, Fondazione Societ{\`a} Italiana di Neurologia.",

year = "2021",

month = feb,

doi = "10.1007/s10072-020-04859-8",

language = "English",

volume = "42",

pages = "711--718",

journal = "Italian Journal of Neurological Sciences",

issn = "1590-1874",

publisher = "Springer-Verlag Italia",

number = "2",

}

TY - JOUR

T1 - Neuropsychiatric symptoms and striatal monoamine availability in early Parkinson’s disease without dementia

AU - Oh, Yoon Sang

AU - Kim, Jean Hee

AU - Yoo, Sang Won

AU - Hwang, Eo Jin

AU - Lyoo, Chul Hyoung

AU - Lee, Kwang Soo

AU - Kim, Joong Seok

N1 - Funding Information: This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT (NRF-2017R1D1A1B06028086 and NRF-2019R1G1A1099554), and by the financial support of the Catholic Medical Center Research Foundation made in the program year of 2019. The funder had no role in study design, data collection and analysis, the decision to publish or manuscript preparation. Publisher Copyright: © 2020, Fondazione Società Italiana di Neurologia.

PY - 2021/2

Y1 - 2021/2

N2 - Background and objective: Neuropsychiatric symptoms are relatively common in Parkinson’s disease (PD). Many studies have revealed that striatal monoamine availability is associated with specific neuropsychiatric symptoms. This study was aimed to investigate the association between comprehensive neuropsychiatric symptoms and striatal monoamine availability in patients with early PD without dementia. Methods: A total of 156 newly diagnosed patients with PD without dementia were included. All patients’ mental and behavioral problems were assessed with the 12-item Neuropsychiatric Inventory (NPI). They underwent positron emission tomography (PET) with 18F-N-(3-fluoropropyl)-2beta-carbon ethoxy-3beta-(4-iodophenyl) nortropane and brain magnetic resonance imaging (MRI). Patients were divided into no neuropsychiatric symptoms and neuropsychiatric symptoms groups according to total NPI score. After normalizing the PET images to spatially normalized MRI, regional standardized uptake value ratios (SUVRs) with a volume of interest template were analyzed for the two groups. Results: Ninety-eight patients had more than one neuropsychiatric symptom. The SUVR of the thalamus in neuropsychiatric symptoms group was significantly lower than the SUVR in no neuropsychiatric symptoms group independent of age, sex, disease duration, or severity of motor symptoms. Conclusion: Patients with early PD who have neuropsychiatric symptoms had a lower monoamine availability in the thalamus than those with no neuropsychiatric symptoms. This finding suggests that decreased monoamine transporter availability in the thalamus may be an imaging biomarker of neuropsychiatric symptoms in patients with PD.

AB - Background and objective: Neuropsychiatric symptoms are relatively common in Parkinson’s disease (PD). Many studies have revealed that striatal monoamine availability is associated with specific neuropsychiatric symptoms. This study was aimed to investigate the association between comprehensive neuropsychiatric symptoms and striatal monoamine availability in patients with early PD without dementia. Methods: A total of 156 newly diagnosed patients with PD without dementia were included. All patients’ mental and behavioral problems were assessed with the 12-item Neuropsychiatric Inventory (NPI). They underwent positron emission tomography (PET) with 18F-N-(3-fluoropropyl)-2beta-carbon ethoxy-3beta-(4-iodophenyl) nortropane and brain magnetic resonance imaging (MRI). Patients were divided into no neuropsychiatric symptoms and neuropsychiatric symptoms groups according to total NPI score. After normalizing the PET images to spatially normalized MRI, regional standardized uptake value ratios (SUVRs) with a volume of interest template were analyzed for the two groups. Results: Ninety-eight patients had more than one neuropsychiatric symptom. The SUVR of the thalamus in neuropsychiatric symptoms group was significantly lower than the SUVR in no neuropsychiatric symptoms group independent of age, sex, disease duration, or severity of motor symptoms. Conclusion: Patients with early PD who have neuropsychiatric symptoms had a lower monoamine availability in the thalamus than those with no neuropsychiatric symptoms. This finding suggests that decreased monoamine transporter availability in the thalamus may be an imaging biomarker of neuropsychiatric symptoms in patients with PD.

UR - http://www.scopus.com/inward/record.url?scp=85094664691&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85094664691&partnerID=8YFLogxK

U2 - 10.1007/s10072-020-04859-8

DO - 10.1007/s10072-020-04859-8

M3 - Article

C2 - 33128104

AN - SCOPUS:85094664691

SN - 1590-1874

VL - 42

SP - 711

EP - 718

JO - Italian Journal of Neurological Sciences

JF - Italian Journal of Neurological Sciences

IS - 2

ER -

Neuropsychiatric symptoms and striatal monoamine availability in early Parkinson’s disease without dementia

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this